RECKITT Benckiser is expanding
the OTC pharmacy eye care
category with the launch of Optrex
ActiMist into Australian community
pharmacies from September.
The product is the UK’s top selling
eye care treatment brand, and is a
quick and easy way of treating dry,
sore and irritated eyes.
Optrex ActiMist is much easier
to use than eye drops because it is
sprayed onto a closed eye; it’s also
safe to use with contact lenses and
can be sprayed over eye make-up.
The spray works by repairing the
lipid layer of the tear film and seals
moisture into the eye.
At an official launch yesterday,
RB’s Vanessa McCutcheon said
about 30% of the population suffer
from dry eyes but most do not seek
treatment, with pharmacists and
pharmacy assistants ideally placed
to educate customers about the
condition and treatment options.
Celebrity Kris Smith is partnering
with an education campaign for
pharmacy staff - for full details see
www.rbhealthhub.com.au.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 13
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.